✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
NRX-1074 is an investigational drug.
There have been 15 clinical trials for NRX-1074. The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2019.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Suicidal Ideation. The leading clinical trial sponsors are Target Health Inc., NeuroRx, Inc., and Naurex, Inc, an affiliate of Allergan plc.
There is one US patent protecting this investigational drug and forty-one international patents.
Recent Clinical Trials for NRX-1074
|NRX101 for Moderate Bipolar Depression and Suicidal Ideation||Bracket, Inc.||Phase 2/Phase 3|
|NRX101 for Moderate Bipolar Depression and Suicidal Ideation||Statistics Collaborative, Inc.||Phase 2/Phase 3|
|NRX101 for Moderate Bipolar Depression and Suicidal Ideation||Target Health Inc.||Phase 2/Phase 3|
Top disease conditions for NRX-1074
Top clinical trial sponsors for NRX-1074
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|NRX-1074||See Plans and Pricing||NMDA receptors modulators and uses thereof||Northwestern University (Evanston, IL)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|NRX-1074||Australia||AU2011215704||2030-02-11||See Plans and Pricing|
|NRX-1074||Australia||AU2012328927||2030-02-11||See Plans and Pricing|
|NRX-1074||Australia||AU2017213587||2030-02-11||See Plans and Pricing|
|NRX-1074||Australia||AU2019204073||2030-02-11||See Plans and Pricing|
|NRX-1074||Brazil||BR112012020142||2030-02-11||See Plans and Pricing|
|NRX-1074||Brazil||BR112014009851||2030-02-11||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|